Summary The immunostimulatory capacities of B7.1-and B7.2-expressing melanoma cells were investigated. A365, 960306 and 950504 melanomas, established from nodular melanoma lesions, were retrovirally transduced. Irradiated B7-, B7.1 + and B7.2+ melanoma cells were co-cultured with autologous or allogeneic peripheral blood mononuclear cells (PBMCs). Proliferation was assessed by [3H]thymidine uptake. mRNA encoding for interleukin 2 (IL-2), IL-4, IL-10 and interferon gamma (IFN-y) was determined. IFN-y, IL-2, IL-4 and IL-10 secretion were quantitated by ELISA. B7.1+ and B7.2+ melanomas induced proliferation of PBMCs and mRNA for IL-2 and IFN-'y. After co-incubation of transduced melanoma cells with PBMCs, high levels of IL-10 were detectable in the supernatant. The presence of neutralizing anti-IL-10 antibodies resulted in enhanced proliferation and IL-2 and IFN-y secretion. Our data indicate that B7.1-and B7.2-transduced melanoma cells trigger lymphocytic proliferation with transcription of IL-10, IL-2 and IFN-y. Blocking of IL-10 augments these effects. Gene therapy protocols using tumour cells as a vaccine have to consider the adverse effects of IL-10.
interleukin 4; interleukin 10; interferon gamma Melanoma is an antigenic tumour (Bystryn, 1989) . Several proteins have been identified that are presented as peptides in the grove of the HLA-I complex. These proteins include members of the MAGE family (Zakut et al, 1993) , gp 100 (Bakker et al, 1994) or tyrosinase .
Although melanoma presents various specific antigens associated with HLA-I, it does not induce an immune response, which results in an elimination of the malignant cells. It is speculated that melanoma cells induce tolerance instead of activation by presenting antigens without the respective co-stimulatory signals (Becker et al, 1993a) . These co-stimulatory signals can be provided by B7. 1 (CD80) or B7.2 (CD86), two molecules capable of delivering co-stimulatory signals to T cells via CD 28 (Becker et al, 1993a; Freeman et al, 1991 Freeman et al, , 1993 Guinan et al, 1994) .
Thus, the immunogenicity of tumour cells is increased if the cells are transfected with human B7.1 (Dohring et al, 1994) .
Expression of the co-stimulatory ligand B7 on melanoma cells has been shown to induce the rejection of a murine melanoma in vivo (Townsend and Allison, 1993) . In addition, treatment of mice bearing an 8-day established melanoma by intraperitoneal injection of B7+ tumour cells resulted in complete tumour regression and cure (Li et al, 1994) . In human melanomas, B7.1 expression was found only in regressing lesions (Denfeld et al, 1995) . Consequently, there are human gene therapy protocols for melanoma that apply melanoma cells genetically engineered to express B7.1 (Fenton et al, 1995) .
We analysed the immunostimulatory potential of a B7.1-and B7.2-transduced human melanoma cell line. We showed that B7. 1-and B7.2-transduced melanoma cells induced proliferation and expression of IL-2 and IFN-y. In addition, we demonstrated that B7.2-transduced melanoma cells induced IL-4, and that the presence of IL-1O suppressed the response of PBMCs.
MATERIALS AND METHODS
Cell culture: melanoma cells and peripheral blood mononuclear cells (PBMCs) Human PBMCs were obtained from healthy volunteers or melanoma patients after informed consent, and were separated by FicollHypaque gradient centrifugation. After separation, the cells were washed twice and immediately resuspended in complete medium (CM) consisting of RPMI 1640 (Gibco/BRL), Eggenstein, Germany) supplemented with 10% of fetal bovine serum (FBS) (Gibco/BRL), 2 mM L-glutamine (Seromed, Berlin, Germany), 10mM sodium pyruvate (Seromed), 100 U ml-1 penicillin (Seromed), 100 mg ml-1 streptomycin (Seromed) and 50 mg of gentamycin (Seromed). Before proliferation experiments, lymphocytes were enriched by plastic adherence over night and collection of the non-adherent cells.
The melanoma cell line A365 (kindly provided by U Reinhold, Department of Dermatology, Bonn, Germany) was also cultured in CM. The 950504 melanoma cells were established from a primary nodular melanoma of a 27-year-old female patient, the 960306 from a skin metastasis of a 36-year-old man as described earlier (Becker et al, 1993b) . Both melanomas expressed human HLA class I, as determined by flow cytometry with the MAb W6/32, and ICAM-1, as determined with the MAb 8.4A6, but they were negative for HLA-DR (data not shown). Table 1 Allogeneic PBMCs were stimulated with A365 melanoma cells that were either untransfected (wt) or transfected with B7.1+ or B7.2. After 2 days of incubation, mRNA was extracted, reverse transcribed and the cDNA amplified with specific primers. PCR products were detected by PCR-ELISA (Dohring et al, 1994) . Amplification was carried out on a DNA Thermal Cycler (PerkinElmer Cetus) using the following conditions: 94°C, 1 min, then 25 cycles of 94°C, 15 s, 60°C, 30 s, 72°C, 45 s, followed by 72°C, 10 min. The amplified PCR product was cloned into the retroviral vector pLXSN (Miller and Rosman, 1989) . The sequence of the B7 inserts was verified to be identical to the published sequence (Freeman et al, 1991 (Freeman et al, , 1993 ) (data not shown). Bacteria were transformed by electroporation, selected on ampicillin-containing agar plates, and plasmid DNA from resistant colonies was purified. The retroviral constructs were packaged in an ecotropic packaging system using the GP+E cell line. Amphotropic packaging was performed using the cell line GP+envAM12 (Markowitz et al, 1988) . As determined by infection on NIH3T3 cell layers, the titre of the viral supematants was in excess of 106 ml-1. These supernatants were used to transduce the A365 and 950504 melanoma cells with B7.1 or B7.2. After 2 days, 1 mg ml-l G418 (Gibco/BRL) was added to the culture for the selection of resistant cells (Dohring et al, 1994) .
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Flow cytometric analysis
The following primary MAbs were used at the concentrations indicated: W6.32 (supernatant purified on protein G sepharose; mouse IgG2a) reacting with a monomorphic determinant on the human HLA class I A, B, C molecules (Brodsky and Parham, 1982;  3.6 gg ml-'); L243 (Becton Dickinson, San Jose, CA, USA; mouse IgG2a) recognizing human HLA class II DR epitopes (Robbins et al, 1987 ; 2.5 jg ml-'); 8.4A6 (Ancell, Bayport, MN, USA; mouse IgGl) recognizing D2 domain of the human CD54 (ICAM-1) molecule (Reilly et al, 1995; 5 .0 jg ml-'). MAB 104 (Immunotech, Marseille, France; mouse IgGI) reacting with B7.1 co-stimulatory molecule (Valle et al, 1990 ; 20 jg ml-'); and BU63 (Ancell; mouse IgGI) reacting with B7.2 co-stimulatory moleculq (Caux et al, 1994;  4.2 jg ml-'). The hCTLA4-IgG fusion protein, consisting of human CTLA4 extracellular domain and human IgGI constant domains, binds to both B7.1 and B7.2 molecules with even higher affinity than CD28, the natural ligand for these receptors (supematant purified on protein G sepharose; Dohring et al, 1994; 2.0 jg ml-'). Reverse transcriptase-polymerase chain reaction (RT-PCR) RNA extraction from PBMCs or melanoma cells was performed as follows: the cell pellet was taken up in buffer A (10 mm Hepes, 10 mm potassium chloride, 1 mm EDTA, 1 mm EGTA) and lysed by vortexing with the addition of 1:16 vol. of 10% NP40. The supernatant was added to an equal volume of buffer B (7 M urea, 1% sodium dodecyl sulphate, 0.35 M sodium chloride). After one phenol-chloroform extraction and one chloroform extraction the RNA was precipitated with ethanol-glycogen and dissolved in DEPC-water. The RNA was quantified by reading absorbance at 260 nm (A260); 2-4 jg of RNA were used to synthesize cDNA PCR DIG labelling nucleotide mix (Boehringer) and with 2.0 ,UM oligonucleotide primers. All cDNAs were first amplified with primers for beta-actin to test the quality and quantity of the cDNA. Only satisfactory cDNA was then subjected to PCR with primers for IL-2, IL-4, IL-10 and IFN-y. Primers were selected using the Oligo Primer Analysis Software program version 4.0 (National Biosciences), except for primers for IL-10, which have published sequences: upper primer pos. 323, 27 nt (Vieira et al, 1991) ; lower primer pos. 646, 27 nt (Butch et al, 1993) . Primer sequences were sent to genebank to exclude cross-binding to other published sequences (Altschul et al; and were published recently (Dummer et al, 1996) . PCR was performed with Perkin Elmer 9600 GenAmp cyclers. Annealing temperatures were 55°C for IFN-y, IL-2 and IL-12p35; 62°C for IL-4, IL-5, IL-7 and IL12p40; and 66°C for IL-10 and IL-13. One cycle (93°C, 2 min 30 s, annealing temperature 1 min 30 s, 72°C, 1 min 30 s) was followed by 30 cycles (94°C, 30 s, annealing temperature, 30 s, 72°C, 1 min 30 s). An aliquot of PCR product was electrophoresed on a 1.6% agarose gel and visualized by ethidium bromide staining. In all PCR reactions, positive controls from various cell lines (see Table  1 ) and water as negative control were included. Figure 1 shows the cytometric analysis of B7.1-and B7.2-positive A365 and A365 wt.
PCR ELISA
For the PCR enzyme-linked immunosorbent assay (ELISA), nucleotide probes were selected with the Oligo software for the sequences of the cDNA fragment amplified (see Table 1 ) by the specific primers and obtained biotinylated (Microsynth, Balgach, Switzerland) . The specifity of all PCR products was confirmed with this method. PCR ELISA was performed according to kit directions (Boehringer). Hybridization was specific at 45'C for all probes except for IL-10. To exclude non-specific binding, hybridization with the IL-10 probes was performed at 50°C. The specific capture probe/PCR product hybrids were bound to streptavidin-coated microtitre plates via the biotin label of the probes. After washing, the immobilized hybrids were treated with anti-DIG peroxidase-conjugated antibody and ABTS, a substrate for the peroxidase. The plates were measured by reading A492 and values that were higher than 2x the reading of the PCR reaction mix with water instead of cDNA were judged to be positive for the expression of the cytokine in question (Dummer et al, 1996) . Table 3 Comparison of cytokine levels after co-incubation of irradiated melanoma cells with allogeneic PBMCs after 2 days in the presence of 10 9g of a neutralizing anti-IL-10 Ab or a control Ab (10 jig of a neutralizing anti-IL- (Figure 3 ). The specifity of all PCR products were confirmed by ELISA reactions after hybridization of biotinylated probes (results are shown in Table 1 ). These cytokines and IL-10 were present in the supernatants of autologous or allogeneic PBMCs with A365 and 960306 melanoma cells (Tables 2 and 3 Comparing the cytokine secretion in the presence of anti-IL-lO Ab with the control, we found an enhancement of IL-2 and IFN-y secretion (Table 3) . IL-4 was only detected in significant amounts if PBMCs were stimulated with B7.2+ melanoma cells without anti-IL-10 Ab (Table 3) .
DISCUSSION
The goal of an effective vaccination therapy of cancer is to induce a specific anti-tumour response mediated by T cells eradicating the disseminated neoplasm. In addition to antigen-specific signals mediated by HLA-associated peptides that are delivered by the T-cell receptor, co-stimulatory signals delivered by CD28 are necessary to achieve a cytotoxic immune response that is also effective against B7-negative tumour cells (D6hring et al, 1994; Guinan et al, 1994) .
We have used a retroviral system to transduce B7.1 (Dohring et al, 1994) and B7.2 into melanoma cells. After selection, more than 90% of the melanoma cells expressed the transgene. They were used to characterize the immune response of allogeneic or autologous PBMCs after co-incubation of irradiated tumour cells to mimic the in vivo situation during a vaccination therapy.
We confirmed that B7+ melanoma cells induce proliferation in PBMCs (Sule-Suso et al, 1995) . The maximum thymidine uptake was already achieved after a 2-day co-incubation and continued for 3-5 days. This proliferation is accompanied by the transcription of IL-2 and IFN-y. Comparing B7.1+ and B7.2+ cells, there were no significant differences regarding proliferation, IL-2 and IFN-y in some experiments. Freeman and co-workers using CHO cells transfected with B7.1 or B7.2 showed that B7.2 induced IL-4, particularly in naive CD4+ CD45RA+ cells (Freeman et al, 1995) . In an experimental allergic encephalomyelitis model, blocking of B7.1 by Ab resulted in a type 1 helper T-cell (THI) response and blocking of B7.2 resulted in a TH2 response in vitro and in vivo (Kuchroo et al, 1995) . The explanation for this observation still remains unclear as CD28 and CTLA-4 fusion proteins bind with indistinguishable affinity to B7.1 and B7.2 respectively (Lanier et al, 1995) . However, CTLA-4 binding is of higher affinity to both B7.1 and B7.2. In the clinical situation of a metastasizing melanoma, a THI response would be preferred. Thus, B7.1 appears to be the more promising transgene than B7.2 for the treatment of cancer (Gajewski et al, 1996) .
The analysis of the cytokine spectrum displayed by melanoma cells (Becker et al, 1994; Chen et al 1994; Mattei et al, 1994; Dummer and Boni, 1995; Kruger-Krasagakes et al, 1995) revealed that melanoma cells transcribe and secrete IL-10. IL-10 is a cytokine with a variety of effects, including inhibition of monocyte major histocompatibility complex (MHC) class II-dependent antigen presentation, THI cytokine production and inhibition of T-cell proliferation (Howard and O'Garra, 1992; deWaal Malefyt et al, 1993; Becker et al, 1994) . In addition, it protects target cells from tumour-and allo-specific cytotoxic T cells and downregulates HLA class I expression (Matsuda et al, 1994) .
In the supematants of melanoma cells alone, we could not detect IL-10 protein in contrast to the supematants of PBMCs coincubated with melanoma cells, probably because of a limited sensitivity of the applied ELISA assay. Therefore, we have to assume that PBMCs and not the melanoma cells are the source for most of the IL-10 found in the supernatants. By a yet undefined mechanism, transduced as well as untransduced melanoma cells induce this cytokine in PBMCs.
We wondered whether the IL-1O has an impact on the stimulatory potential of B7+ melanoma cells. The presence of a neutralizing Ab against IL-10, but not against IL-7, resulted in a considerable increase of the proliferation induced by the melanoma cells using allogeneic as well as autologous melanoma cells. Even more pronounced was the effect of IL-10 blockage on IL-2 and IFN-y secretion, which was increased by at least a factor of 50. These data clearly suggest antagonizing effects of IL-IO.
We conclude that transduction of B7.1 into melanotic tumour cells may not be sufficient to establish an efficient T-cell response because of tumour cell-induced inhibitory factors, such as IL-10. 
